NCT03257852 - A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

September 19, 2018

Study Completion Date

October 16, 2018

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

ASP5094

intravenously administration

DRUG

Placebo

intravenously administration

OTHER

Methotrexate therapy

MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.

Trial Locations (31)

Unknown

Site JP00002, Asahikawa

Site JP00027, Asahikawa

Site JP00029, Beppu

Site JP00015, Chiba

Site JP00008, Fukuoka

Site JP00009, Fukuoka

Site JP00026, Fukuoka

Site JP00016, Ichinomiya

Site JP00012, Kanuma

Site JP00028, Kawachi-Nagano

Site JP00005, Kitamoto

Site JP00025, Kobe

Site JP00030, Kobe

Site JP00010, Kumamoto

Site JP00006, Kyoto

Site JP00018, Meguro City

Site JP00020, Nagano

Site JP00014, Nagoya

Site JP00022, Okayama

Site JP00011, Ōita

Site JP00003, Ōsaki

Site JP00019, Sagamihara

Site JP00007, Sanuki

Site JP00001, Sapporo

Site JP00023, Shimonoseki

Site JP00021, Shizuoka

Site JP00004, Takasaki

Site JP00017, Tomakomai

Site JP00013, Toyohashi

Site JP00024, Tsukuba

Site JP00031, Yokohama